Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)-Reference-Cited by-同舟云学术

Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Tougeron David¹²^ORCID,Emambux Sheik³,Favot Laure²,Lecomte Thierry⁴⁵,Wierzbicka-Hainaut Ewa²⁶,Samimi Mahtab⁷,Frouin Eric²⁸,Azzopardi Nicolas⁵^ORCID,Chevrier Jocelyn²,Serres Laura¹,Godet Julie⁸,Levillain Pierre⁸,Paintaud Gilles⁵⁹,Ferru Aurélie³,Rouleau Laetitia¹,Delwail Adriana¹⁰,Silvain Christine¹²,Tasu Jean-Pierre¹¹¹²,Morel Franck²,Ragot Stéphanie¹³,Lecron Jean-Claude²¹⁴

Affiliation:

1. Gastroenterology Department, Poitiers University Hospital, Poitiers, France

2. Laboratory Inflammation, Tissus Epithéliaux Et Cytokines, EA 4331, Poitiers University, Poitiers, France

3. Medical Oncology Department, Poitiers University Hospital, Poitiers, France

4. Gastroenterology Department, Tours University Hospital, Tours, France

5. Tours University, EA7501 GICC, Team PATCH, Tours, France, Tours, France

6. Dermatology Department, Poitiers University Hospital, Poitiers, France

7. Dermatology Department, Tours University Hospital, ISP1282 INRA, Université De Tours, Tours, France

8. Pathology Department, Poitiers University Hospital, Poitiers, France

9. Pharmacology Department, Tours University Hospital, Tours, France

10. ImageUP, Plate-forme d’Imagerie and Laboratoire Signalisation Et Transport Ioniques Membranaires ERL CNRS 7003/EA 7349, Poitiers University, Poitiers, France

11. Radiology Department, Poitiers University Hospital, Poitiers, France

12. LaTIM, INSERM U1101, Brest, France

13. Cic Inserm 1402, Poitiers University Hospital, Poitiers, France

14. Immunology/inflammation Laboratory, Poitiers University Hospital, Poitiers, France

Funder

Ligue contre le Cancer of Vienne, Deux-Sèvres, Charente et Charente-Maritime Departments

Institut de Recherche des Maladies de l’Appareil Digestif

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1848058

Reference51 articles.

1. Fact Sheets by Cancer [Internet]. [accessed 2018 Jul 9]. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

3. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

4. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

5. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Notable correlation between serum epidermal growth factor values and inflammatory status in patients with COVID‐19;Immunity, Inflammation and Disease;2024-08

2. Impact of epidermal growth factor receptor and mitogen-activated kinase inhibition on hair follicles (HFs): partial HF immune privilege collapse and excessive interleukin-33 secretion;British Journal of Dermatology;2024-07-06

3. Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege;British Journal of Dermatology;2024-06-11

4. Immune Reactions in Major Types of Oncological Treatment;International Journal of Molecular Sciences;2023-07-09

5. Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?;Cancers;2023-03-08